Merck & Co is a global drugmaker that sells life-saving medicines and vaccines to hospitals, clinics, and pharmacies. It generated $64.93 billion in revenue last year, led by its cancer drug Keytruda which is currently the top-selling drug in the world. While many legacy pharmaceutical giants are struggling to find new growth, Merck has maintained steady momentum by expanding its oncology treatments and building a multi-billion dollar animal health business.
The investment thesis on Merck is that it is successfully building a bridge to survive the 2028 "patent cliff" when its flagship drug, Keytruda, loses its legal protection. Investors have long feared a collapse in earnings once cheaper copies of Keytruda enter the market, but Merck is countering this by launching a easier-to-inject version and acquiring a new generation of heart and blood medicines. If these new launches offset the eventual loss of exclusivity, the company's high margins and cash flow remain intact.
We think Merck is significantly better prepared for its patent challenges than the market currently acknowledges, making it a rare value opportunity in big pharma. The recent launch of Winrevair is already beating expectations, and the company has been aggressive in using its cash to buy promising smaller biotech firms.
Merck's stock has climbed steadily over the last five years but recently cooled off. The company is doing well because its world-famous cancer drug and new treatments for stomach diseases are selling fast. Investors are watching closely to see if these new medicines can keep the company growing once the patent on its top drug expires in a few years.
What does it do?
Merck & Co is a mature healthcare business that earns money by discovering, manufacturing, and selling prescription medicines, vaccines, and animal health products. The company operates through a research-heavy model where it spends billions on clinical trials to prove a drug is safe and effective. Once a drug is approved by regulators, Merck holds a patent that prevents others from making it for several years, allowing the company to charge premium prices. These products are sold primarily to drug wholesalers, retail pharmacies, and government health agencies worldwide.
Where does revenue come from?
Merck earns the vast majority of its money from human medicines, but it also owns one of the world's largest animal health businesses. The Pharmaceuticals segment accounts for roughly 88% of sales, headlined by oncology drugs like Keytruda and vaccines like Gardasil for HPV. The remaining 12% comes from Animal Health, which sells vaccines and medicines for livestock and pets, such as the Bravecto flea and tick treatment.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Merck serves millions of patients and pet owners through a global network of hospitals, clinics, and veterinarians. While patients eventually use the medicine, the actual buyers are usually large distributors or government health systems. In oncology, its primary drug Keytruda generated $8.03 billion in sales in just the first quarter of 2026, serving hundreds of thousands of cancer patients globally. The Animal Health segment brought in $1.79 billion during the same period, with the Bravecto line alone contributing $379 million in quarterly sales from pet owners.
What gives it staying power?
Merck’s durability comes from its massive intellectual property portfolio and the high cost for competitors to develop rival drugs. Developing a new medicine takes over a decade and costs billions, creating a natural barrier that keeps most competitors out. Once a drug is part of a standard hospital treatment plan, switching costs for doctors are high.
Where is it headed?
Merck is betting its future on a massive expansion into cardiovascular and respiratory medicines to diversify away from its oncology focus. CEO Robert Davis is leading an aggressive acquisition strategy, including recent multi-billion dollar deals for Acceleron and Terns Pharmaceuticals. This shift is intended to create a new "cardio-pulmonary" pillar that can generate billions in annual revenue by the end of the decade.
Revenue has entered a new phase of steady growth, reaching $64.93 billion in 2025 as the company successfully expands its oncology and cardiovascular sales. The business is currently accelerating, with Q1 2026 sales rising 5% despite significant currency headwinds. This growth is increasingly diversified, as newer products now contribute more than $1 billion in combined quarterly growth.
Cash generation remains a defining strength, with free cash flow of $12.36 billion in 2025 supporting an aggressive acquisition strategy. While free cash flow can fluctuate based on the timing of multi-billion dollar R&D milestones, the underlying business typically converts over 70% of its earnings into actual cash. This high cash quality allows Merck to fund its dividend and its heavy pipeline investments simultaneously.
The balance sheet is managed with a focus on acquisition capacity, carrying a debt-to-equity ratio of 1.07x following several major biotech purchases. While the company carries significant debt, its interest coverage is comfortably high due to its $23.49 billion in operating income. Merck is sitting on enough liquidity to continue its strategy of buying mid-sized biotech companies to fill its pipeline.
Merck is a financially dominant enterprise that uses its massive oncology cash flows to fund its next decade of growth through scientific acquisitions.
Keytruda sales grew 12% to reach $8.03 billion in the most recent quarter, proving the oncology franchise is still expanding even at its massive scale. This growth is being driven by strong uptake in earlier-stage cancers, which keeps patients on the drug for longer periods. Simultaneously, the Winrevair launch is hyper-scaling, with sales nearly doubling year-over-year to $525 million.
Gardasil vaccine sales fell 19% this quarter to $1.07 billion, primarily due to lower demand and purchasing delays in China. This is the second largest franchise for Merck, and a prolonged slowdown in the Chinese market would force the company to rely even more heavily on its oncology pipeline. Management is currently investigating whether this is a temporary inventory issue or a structural shift in demand.
The global pharmaceutical market is roughly $1.6 trillion today and grows at a steady 5% annually, likely exceeding $2.0 trillion by 2030. This is a mature industry where pricing power is protected by government-granted patents, though it faces structural pressure from government price negotiations and the "patent cliff" where drugs lose protection. Merck stands as a top-tier global leader in this market, possessing the scale to fund the multi-billion dollar R&D budgets required to stay competitive.
Competitive dynamics in big pharma are defined by the "race to first" in clinical trials, where the first drug to market often captures 70% of the long-term profit. While barriers to entry are extreme due to regulatory and R&D costs, the industry is increasingly focused on a few high-value areas like oncology and immunology. Pricing power remains structural until patents expire, after which it collapses overnight.
Bristol-Myers Squibb is the most direct threat, as its drug Opdivo competes head-to-head with Keytruda in nearly every major cancer type. Roche and AstraZeneca are also dangerous because they possess deep portfolios of combination therapies that can push Merck out of specific cancer treatments. The most dangerous threat is the rise of biosimilars, which are cheaper versions of biological drugs that will target Keytruda starting in 2028.
Merck is currently holding its ground and even gaining share in earlier-stage cancer treatments. Its 12% growth in Keytruda sales outpaces many rivals, proving that its data and clinical reputation are winning over doctors. Merck is successfully defending its market share through superior clinical evidence.
Merck’s primary protection is its massive portfolio of patents and intellectual property, which grants it a legal monopoly on life-saving drugs like Keytruda and Gardasil. This IP moat is reinforced by "data moats," where years of clinical trial success make doctors much more likely to prescribe a Merck drug over a newer, unproven rival. The strength of this moat is visible in Merck's 75.9% gross margins.
The combination of 13.3% ROIC and high retention in its oncology business proves that Merck has a durable advantage, not just a lucky cycle. While the 2028 patent cliff is a real risk, the company’s ability to generate $18 billion in annual net income provides the "dry powder" needed to buy its way into new moats. The numbers confirm a Wide moat that is currently stable.
The forward-looking verdict is that Merck’s moat is widening in cardiovascular health but faces an eventual challenge in oncology. The launch of subcutaneous Keytruda is the single most important signal for moat durability.
Raised 2026 sales guidance and delivered 12% Keytruda growth in the latest quarter.
Allocated $9 billion for the Cidara acquisition to bolster the long-term immunology pipeline.
CEO Robert Davis holds a significant stake in Merck stock and pay is performance-linked.
Capital Allocation Track Record
Robert Davis has demonstrated exceptional strategic judgment by aggressively pivoting Merck away from its total dependence on a single drug. Since taking over as CEO, Davis has used Merck's massive cash flow to strike several major deals that have already begun to produce results, most notably the Acceleron deal which delivered Winrevair. The management team has been consistently honest about the upcoming 2028 patent challenges, and their proactive approach to filling the revenue gap with high-margin heart and vaccine products has earned them significant credibility with long-term owners.
The investment thesis is well-insulated from key-person risk due to a deep bench of experienced scientific and manufacturing leaders. While Robert Davis is the strategic architect, the core value of Merck lives in its Research Laboratories led by Dean Li and its massive global manufacturing division. The board is independent and has shown a clear preference for disciplined, scientific leaders, meaning a change at the top would likely result in a continuation of the current strategy rather than a volatile pivot. Merck does not suffer from the founder-driven volatility seen in younger biotech firms, making it a stable choice for defensive investors.
We expect revenue to grow from $66.7B in FY2026 to $68.6B in FY2031 (~1% CAGR), with EPS growing from $5.14 to $9.65 (~13% CAGR). Revenue growth slows and eventually declines as the primary oncology patent for Keytruda expires, leading to increased competition from biosimilars. Operating margins remain robust as the company pivots toward its high-margin pipeline of antibody-drug conjugates and cardiovascular therapies. Operating margin expected to reach ~34% by FY2031.
Winrevair becomes the primary heart failure drug of the next decade. If Winrevair sustains its 80% plus growth, it provides a multi billion dollar revenue pillar that protects the dividend post 2028.
Subcutaneous Keytruda prevents biosimilar competition from taking market share. An easier self injectable version of Keytruda could lock in patients and doctors before cheaper generic versions arrive.
Animal Health segment expands margins via pet healthcare premiumization. As pet owners spend more on specialized medicines, Merck’s animal health business becomes a high margin cash machine.
Gardasil demand in China remains depressed for multiple quarters. If the slowdown in China is structural rather than temporary, Merck loses its most important growth driver outside of oncology.
Clinical failure of major Phase 3 pipeline assets before 2028. If Merck’s acquired drugs fail to reach the market, it will be left with a massive revenue hole when Keytruda patents expire.
U.S. government drug price negotiations significantly lower oncology margins. New federal powers to negotiate prices could target Merck’s highest profit drugs, compressing margins across the entire Pharmaceutical segment.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach applied to FY2027 earnings to look past the current year's acquisition-driven volatility. This framework fits Merck because the company's recent GAAP net loss was caused by a one-time $9B acquisition charge, making current-year earnings a poor signal of long-term value; looking two years out provides a cleaner view of the "post-cliff bridge" earning power.
Projected FY2027 EPS of $9.64 multiplied by a 16x multiple gives a per-share fair value of $154. Our 16x multiple sits at the high end of the mature pharma peer range of 12-17x (Pfizer 12x, AbbVie 16.5x), a premium justified by Merck's best-in-class oncology margins and successful cardiometabolic diversification. We use the FY2027 EPS of $9.64 from the projection engine instead of the FY2026 figure ($5.14) because the 2026 number is artificially depressed by the Cidara acquisition financing and integration costs.
Cross-checked with an EV/Revenue approach (FY+2 revenue $74B × 5.0x peer multiple), we get a fair value of $132 — within 15% of our $154 P/E result, confirming the valuation. A 5x revenue multiple is consistent with high-margin pharmaceutical leaders like AbbVie and reflects the market's willingness to pay for Merck's diversified "diversification wall" revenue. The slight difference between the two methods is expected, as the P/E approach more accurately captures the high profitability of the core Keytruda franchise compared to the broader revenue-based peer average.
We're assuming that Winrevair and the newer immunology pipeline candidates can generate over $10B in combined annual revenue by 2028. This is supported by recent clinical wins in ulcerative colitis and the strong initial launch trajectory of Winrevair, which generated $419M in its partial first year. Management's "One Pipeline" strategy appears to be successfully replacing future lost revenue with high-margin biologic therapies.
We're assuming Merck successfully transitions a material portion of the Keytruda patient base to the subcutaneous (under-the-skin) version before 2028. This formulation typically grants new patent protection and protects the moat against generic competition. Given Merck's historical success in lifecycle management and the clear patient preference for shorter administration times, this transition is the most likely path to maintaining oncology dominance.
The single biggest risk is that the "diversification wall" of new products fails to scale fast enough to offset the massive revenue loss when Keytruda loses patent protection in 2028. If new launches like Winrevair underperform, the market multiple will likely compress from 16x to 11x, knocking roughly $45 off the per-share fair value. Watch for any quarterly deceleration in the "New Products" revenue segment as an early signal.
Bear case ($125): Winrevair (pulmonary hypertension) adoption stalls below $1.5B in annual sales through FY2027; or FDA delays the approval of the subcutaneous Keytruda formulation by more than 12 months.
Bull case ($185): Cardiopulmonary pipeline revenue exceeds $5B by FY2028, effectively erasing "one-trick pony" fears; or Operating margins expand 300bps faster than expected as R&D for the "diversification wall" begins to crest.
Clearthesis wrote this report from 39 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because Merck is successfully proving that its future growth can outpace the eventual loss of its flagship drug. Recent trial success for its ulcerative colitis drug and consistent expansion into animal health provide tangible evidence that Merck is diversifying away from its total reliance on cancer treatment Keytruda.
Skeptics think that Merck will struggle to replace the massive revenue hole left when Keytruda loses its patent protection in 2028. They argue that no amount of smaller drug approvals can realistically replicate the world-beating profits of a dominant blockbuster medicine, making future earnings growth math extremely difficult to sustain.